• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Know Labs Inc.

    10/25/23 7:27:11 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email
    SC 13D 1 ea187306-13dbaszucki_know.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2 to Schedule 13G)

     
    KNOW LABS, INC.
     
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
     
    (Title of Class of Securities)
     
    499238103
     
    (CUSIP Number)
     
    Todd Baszucki  
    395 Del Monte Center, #306
    Monterey, CA 93940
    TEL: 831-402-5699
     
    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)
     
    October 16, 2023
     
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 499238103

     

    1. Name of Reporting Persons.
      Todd Baszucki
       
      I.R.S. Identification Nos. of above persons (entities only).
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
       
    3. SEC Use Only
       
       
    4. Source of Funds (See Instructions):     PF
       
       
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ☐
       
       
    6. Citizenship or Place of Organization:     USA
       
       

     

     

    Number of Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    7. Sole Voting Power     17,200,000

     
     
    8. Shared Voting Power     0
     
     
    9. Sole Dispositive Power     17,200,000
     
     
    10. Shared Dispositive Power     0
     
     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person     17,200,000
       
       
    12. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      ☒
       
      This excludes warrants for the purchase of 1,000,000 shares of common stock.
    13. Percent of Class Represented by Amount in Row (9)     21.4% 1
       
       
    14. Type of Reporting Person (See Instructions)     IN
       
       

     

     

    1Based   on 80,358,463 shares of Common Stock outstanding as of October 16, 2023, as confirmed by the Issuer.

     

    - 2 -

     

     

    Item 1. Security and Issuer

     

    Todd Baszucki (the “Reporting Person”) previously filed a Schedule 13G on April 12, 2022, as amended February 14, 2023 (the “Schedule 13G”). This Schedule 13D (this “Schedule 13D”) relates to the common stock (the “Common Stock”) of Know Labs, Inc. fka Visualant, Incorporated, a Nevada corporation (the “Issuer” or “Registrant”), and amends the Schedule 13G.  The address of the principal executive offices of the Issuer is 500 Union St, Suite 810, Seattle, WA 98101, its telephone number is (206)903-1351

     

    Item 2. Identity and Background

     

    (a)This Schedule 13D is being filed by Todd Baszucki (the “Reporting Person”).

     

    (b)The principal business address for the Reporting Person is 395 Del Monte Center, #306
    Monterey, CA 93940

     

    (c)The principal occupation of the Reporting Person is a self employed, private investor, the business address of which is 395 Del Monte Center, #306 Monterey, CA 93940.

     

    (d)The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.

     

    (e)During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)The Reporting Person is a citizen of the United States.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    The Reporting Person used cash to make the purchases of Common Stock.

     

    Item 4. Purpose of Transaction

     

    The Common Stock was acquired for, and are being held for, investment purposes. Depending on the factors discussed herein, the Reporting Person may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the shares of Common Stock held by the Reporting Person in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Person to other entities. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person’s review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer’s business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, investor’s need for liquidity, and other future developments. 

     

    The Reporting Person has no present intention to sell any shares of Common Stock, although any Reporting Person could determine from time to time, based upon the same factors listed above for purchases, to sell some or all of the shares of Common Stock held by such Reporting Person.

     

    The Reporting Person does not have any plans or intentions that would result in any of the actions or transactions described in clauses (a)through (j) of Item 4 of Schedule 13D, except as previously disclosed in this Schedule 13D, or as set forth above.

     

    Item 5. Interest in Securities of the Issuer

     

    (a) As of October 16, 2023, Mr. Baszucki beneficially owns 17,200,000 shares of Common Stock individually. This total includes all shares of common stock acquired in private placements through September 30, 2023, open market acquisitions and dispositions of shares of common stock through September 30, 2023, and excludes warrants for the purchase of 1,000,000 shares of common stock.

     

    Mr. Baszucki beneficially owns 21.4% of the Common Stock outstanding, based on total shares of Common Stock outstanding as of Octoober 16, 2023 of 80,358,463 shares of Common Stock, as confirmed by the Issuer.

     

    (b) As of October 16, 2023, Mr. Baszucki had sole voting power and sole dispositive power with respect to 17,200,000 common stock shares, excluding an additional 1,000,000 shares of Common Stock assuming exercise of all warrants to purchase common stock (which have been excluded from the Reporting Person’s total voting power).

     

    (c) Within the 60 days prior to the filing of this Schedule 13D, Mr. Baszucki acquired /disposed of the following securities of the Issuer:

     

    - 3 -

     

     

    On August 25, 2023, Mr. Baszucki purchased 10,000 shares of common stock at a purchase price of $0.6799 per shares through open market purchases.

     

    On September 7, 2023, Mr. Baszucki purchased 20,000 shares of common stock at a purchase price of $0.6299 per share through open market purchases.

     

    September 15, 2023, Mr. Baszucki purchased 245,545 shares of common stock at a purchase price of $0.5675 per share through open market purchases.

     

    On September 29, 2023, Mr. Baszucki purchased 14,000,000 shares of common stock at $0.25 per share pursuant to Issuer’s Registered Offering on Form S-1 declared effective September 26, 2023 (Registration No. 333-274350).

     

    September 25, 2023, Mr. Baszucki sold 96,517 shares of common stock at a sales price of $0.4538 per share through open market sales.

     

    September 26, 2023, Mr. Baszucki sold 200,000 shares of common stock at a sales price of $0.3607 per share through open market sales.

     

    September 27, 2023, Mr. Baszucki sold 249,300 shares of common stock at a sales price of $0.2360 per share through open market sales.

     

    September 28, 2023, Mr. Baszucki sold 317,891 shares of common stock at a sales price of $0.2406 per share through open market sales.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Except as described herein, the Reporting Person nor any other person referred to in Item 2 herein, has any contract, arrangements understandings or relationship (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

     

    Item 7. Material to Be Filed as Exhibits

     

    None.

     

    - 4 -

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 25, 2023 By: /s/ Todd Baszucki
        Name: Todd Baszucki

     

     

    - 5 -

     

     

    Get the next $KNW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Leadership Updates

    Live Leadership Updates

    See more
    • Know Labs Appoints Chris Somogyi as President, International

      Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

      5/16/24 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Medical and Scientific Advisory Board

      New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

      12/14/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Board of Directors

      Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

      11/8/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    SEC Filings

    See more
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/6/25 9:00:35 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/4/25 5:07:06 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form 10-Q filed by Know Labs Inc.

      10-Q - KNOW LABS, INC. (0001074828) (Filer)

      5/14/25 4:24:08 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      6/3/24 2:11:39 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D filed by Know Labs Inc.

      SC 13D - KNOW LABS, INC. (0001074828) (Subject)

      10/25/23 7:27:11 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      10/19/23 6:32:18 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

      Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

      6/6/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Sensor Non-Invasively Identifies pH Levels in Real Time

      Significant Applications in Health Care, Food Quality and Safety and More Know Labs, Inc. (NYSE:KNW) is pleased to announce that it has completed extensive research in its laboratory utilizing its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify changes in pH levels in real time. The research has been submitted for peer reviewed publication. The research is available for review today here on the Company's website at www.knowlabs.co. An abstract of the paper states, "We describe an experiment in which we employ a radio frequency sensor to measure pH changes in a liquid solution. The experiment is novel in a few ways. First, the sensor does not have cont

      3/19/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs to Attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      The company to meet with potential strategic partners to discuss collaborating on advancing clinical research of its non-invasive blood glucose monitor Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology with its Radio Frequency Dialectic Spectroscopy (RFDS) platform, today announced the company will be attending The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair in Amsterdam, Netherlands on March 19-22, 2025. The Company will share updates on the development of its non-invasive blood glucose monitor, since last year's conference, and discuss opportunities for collaboration and partnership

      3/18/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Erickson Ronald P

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      6/4/25 4:15:21 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Takesako Ichiro John Paul was granted 25,000 shares, increasing direct ownership by 645% to 28,875 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:32 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Ellingson Larry K was granted 25,000 shares, increasing direct ownership by 6,188% to 25,404 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:34 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Financials

    Live finance-specific insights

    See more
    • Know Labs, Inc. Reports Third Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

      8/14/23 4:15:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports Second Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

      5/15/23 4:05:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports First Quarter 2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

      2/14/23 4:00:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials